Phathom Pharmaceuticals, Inc.
PHAT
$9.58
$0.404.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 88.02% | 104.43% | 94.12% | 202.74% | 439.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 88.02% | 104.43% | 94.12% | 202.74% | 439.36% |
| Cost of Revenue | 199.64% | 222.13% | 100.47% | 162.73% | 266.13% |
| Gross Profit | 71.70% | 86.75% | 93.18% | 209.47% | 479.44% |
| SG&A Expenses | -35.14% | -42.83% | -36.92% | -32.25% | 12.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.31% | -31.29% | -28.70% | -25.67% | 17.49% |
| Operating Income | 93.38% | 80.37% | 90.02% | 78.43% | 22.48% |
| Income Before Tax | 76.81% | 67.80% | 71.59% | 64.98% | 17.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 76.81% | 67.80% | 71.59% | 64.98% | 17.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.81% | 67.80% | 71.59% | 64.98% | 17.10% |
| EBIT | 93.38% | 80.37% | 90.02% | 78.43% | 22.48% |
| EBITDA | 93.56% | 80.47% | 90.21% | 78.59% | 22.50% |
| EPS Basic | 79.93% | 71.76% | 72.66% | 69.16% | 33.01% |
| Normalized Basic EPS | 79.93% | 71.76% | 72.66% | 69.16% | 33.01% |
| EPS Diluted | 79.93% | 71.76% | 72.66% | 69.16% | 33.01% |
| Normalized Diluted EPS | 79.93% | 71.76% | 72.66% | 69.16% | 33.01% |
| Average Basic Shares Outstanding | 15.57% | 14.01% | 3.90% | 13.57% | 23.75% |
| Average Diluted Shares Outstanding | 15.57% | 14.01% | 3.90% | 13.57% | 23.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |